SCHEMBL1880472

SCHEMBL1880472

N#Cc1cccc2cc(CO)c(-c3ccccc3)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
HTT P42858 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
KMT2A Q03164 2/20 0.39
MAPK1 P28482 2/20 0.39
MAPT P10636 1/20 0.39
ADORA2A P29274 3/20 0.38
ADORA1 P30542 3/20 0.38
MEN1 O00255 1/20 0.38
ADORA2B P29275 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
GAA P10253 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDR P35968 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1887862 0.78 MEN1 (0.48) ALDH1A1KDM4EKMT2AMAPK1MEN1
SCHEMBL1880602 0.78 DHODH (0.46) ALDH1A1KDM4EKMT2AADORA2AADORA1
SCHEMBL1889250 0.77 MEN1 (0.43) ALDH1A1KDM4EKMT2AMAPTMEN1
SCHEMBL1886897 0.75 PDE10A (0.46) ALDH1A1KDM4ELMNAKMT2AMAPK1
SCHEMBL10379389 0.74 ALDH1A1 (0.59) ALDH1A1KDM4EHTTRXFP1LMNA
SCHEMBL1886855 0.73 PLAU (0.39) ADORA2AADORA1ADORA2BCNR1CHUK
SCHEMBL1882100 0.72 PDE10A (0.56) ALDH1A1KDM4ELMNAKMT2AMAPT
SCHEMBL19864357 0.71 PIK3CD (0.42) ALDH1A1MAPTADORA2AADORA1ADORA2B
SCHEMBL17442858 0.70 KMT2A (0.44) ALDH1A1KDM4ERXFP1KMT2AMAPK1
SCHEMBL1878618 0.69 ATM (0.52) KMT2AMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE ALDH1A1 4276/4885KDM4E 2230/4885HTT 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.